What Are Integrins and What Is Their Role in the Body?

Integrins are a family of receptor proteins that sit on the surface of nearly every cell in your body, physically connecting each cell to its surroundings and relaying information in both directions across the cell membrane. They are large molecules made of two linked subunits, and in humans there are 24 known pairings, each tuned to recognize specific partners in the tissues outside the cell. Far from being passive anchors, integrins actively regulate how cells stick together, move, divide, and even whether they live or die. Their influence spans wound healing, immune defense, blood clotting, bone development, and cancer, making them one of the most versatile protein families in human biology.

How Integrins Are Built

Each integrin is a heterodimer, meaning it is assembled from two different protein chains called alpha and beta subunits. The human genome encodes 18 alpha and 8 beta subunits, which combine in specific pairs to form the 24 distinct integrins found in our cells. The overall shape resembles a large head sitting atop two leg-like stalks, with the head region containing the sites where the integrin grabs onto molecules outside the cell and where the two subunits meet each other.¹ The legs extend down through the cell membrane, with short tails dangling inside the cell where they link up with the internal scaffolding.

The 24 integrins are not interchangeable. Different combinations recognize different targets: some bind collagen, others bind proteins in blood, and still others latch onto specific partners on neighboring cells. Recent computational modeling has successfully predicted the structures of all 24 human integrin heterodimers, confirming that while they share the same general architecture, each pairing has subtle structural differences that explain its unique binding preferences.²

Activation and the “On/Off Switch”

One of the most distinctive features of integrins is that they are not always “on.” In a resting cell, integrins fold into a bent, compact shape that has low affinity for anything outside. When the cell receives a signal that it needs to grab onto something, internal proteins push the integrin into an extended, open conformation. This process is called inside-out signaling, and two key players drive it: talin and kindlin, which bind the integrin’s inner tail and cooperate to flip the switch.³ Research has shown that the rod domain of talin plays a previously unrecognized role in how strongly integrins bind to certain ligands, particularly large, multivalent ones.⁴

Once activated and bound to an external partner, the integrin sends signals back into the cell through what is called outside-in signaling. This return signal recruits additional proteins and triggers cascades that tell the cell to spread, migrate, or change its gene expression. The enzyme focal adhesion kinase is one of the central relays in this process, translating the integrin’s external grip into internal cellular responses like movement and growth.⁵ This two-way communication is what sets integrins apart from simpler glue-like molecules: they do not just hold things together, they constantly inform the cell about its environment.

Anchoring Cells and Connecting the Skeleton

The most basic job of integrins is attaching cells to the meshwork of proteins that fills the space between them, known as the extracellular matrix. But attachment alone would not be very useful without a physical connection to the machinery inside the cell. Integrins provide that link by associating with a large complex of proteins that tie into the actin cytoskeleton, the internal framework that gives cells their shape and allows them to exert force.⁶ The assembly of this linkage is rapid: as soon as an integrin binds an external matrix protein, scaffolding proteins like talin and paxillin are recruited to its cytoplasmic tail within seconds.⁷

In skin, a specific integrin called α6β4 plays a specialized anchoring role. Rather than connecting to actin filaments like most integrins, α6β4 hooks into structures called hemidesmosomes, which rivet the bottom layer of skin cells to the underlying tissue.⁸ The β4 subunit’s unusually long cytoplasmic tail is what makes this possible; a specific 303-amino-acid stretch within it mediates the interaction with the hemidesmosome’s internal components.⁹ Genetic defects in this integrin cause severe blistering skin diseases, because without it the skin literally cannot hold itself together.

How Integrins Drive Cell Movement

Cells do not crawl by accident. Migration requires a coordinated cycle of gripping the surface ahead, pulling forward, and letting go behind. Integrins are the grip. At the leading edge of a moving cell, integrins engage the matrix, forming new adhesion points. At the trailing edge, older adhesions are disassembled. The integrins from those disassembled sites are swallowed back into the cell through endocytosis and then recycled to the front, ready to be used again.¹⁰

This recycling loop is remarkably specific. After internalization, β1 integrins pass through a series of internal sorting compartments. If a protein called IFT20 is missing, the integrins get stuck in the early sorting stage and never make it back to the cell surface, stalling migration and preventing the cell from forming new adhesion points at its front.¹¹ Cancer researchers are paying close attention to this recycling machinery, because tumor cells that hijack it can become more mobile and invasive. One study found that a protein called LAPTM4B-35 stabilizes cell protrusions and speeds up integrin β1 recycling, promoting cancer cell dissemination in a zebrafish model.¹²

Blood Clotting and the Platelet Integrin

If you cut yourself, the bleeding stops thanks in large part to a single integrin: αIIbβ3, found on the surface of platelets. In circulating blood, this integrin is kept in a low-affinity, inactive state. When a blood vessel is damaged and platelets are activated, αIIbβ3 rapidly switches to a high-affinity conformation and binds fibrinogen, the rope-like protein that crosslinks platelets into a clot. Subsequent outside-in signaling through αIIbβ3 drives platelet spreading, aggregation, and the contraction that tightens the clot.¹³

Because αIIbβ3 is the final step in clot formation, it has been a target for anti-clotting drugs. The integrin’s ligand-binding pocket recognizes short amino-acid sequences, particularly the tripeptide RGD (arginine-glycine-aspartate), which appears in fibrinogen and many other matrix proteins. How tightly integrins hold onto RGD depends on a metal ion (called the MIDAS ion) in the binding site; simulations have shown that a single tightly coordinated water molecule stabilizes this bond under mechanical stress.¹⁴ Even small changes in the amino acids flanking RGD can dramatically shift which integrin the sequence binds: swapping just one residue can switch a molecule’s preference from the platelet integrin to the vitronectin receptor on other cell types.¹⁵ That exquisite specificity matters both for understanding clotting and for designing drugs that block one integrin without interfering with others.

Integrins in the Immune System

When your body detects an infection or injury, immune cells need to leave the bloodstream and travel to the site of trouble. Integrins make this possible. Two integrins are central to the process: LFA-1 (αLβ2), which is found exclusively on white blood cells, and VLA-4 (α4β1), which appears on most leukocytes. LFA-1 binds to ICAM molecules on the inner lining of blood vessels, while VLA-4 binds to VCAM-1. Together, these interactions allow immune cells to slow down, stick to the vessel wall, and then squeeze between endothelial cells to reach the inflamed tissue.¹⁶

Beyond trafficking, integrins also shape the immune response itself. VLA-4 is not just an adhesion molecule; it localizes to the immune synapse, the specialized contact zone between a T cell and the cell presenting an antigen, and it sends co-stimulatory signals that help push T cells toward a particular type of inflammatory response.¹⁷ This dual role makes immune-cell integrins attractive drug targets in autoimmune diseases where immune trafficking goes haywire. Natalizumab, used for multiple sclerosis, works by blocking VLA-4 and preventing immune cells from crossing into the brain.

Sensing Stiffness and Mechanical Forces

Cells are not just passive passengers glued in place by integrins. They actively push and pull on their surroundings, and integrins are the sensors that tell them how stiff or soft the matrix is. This process, called mechanotransduction, influences everything from cell shape to whether a stem cell becomes a bone cell or a fat cell. Integrins bind extracellular matrix fibers on the outside and link to actin filaments on the inside, forming a physical bridge that transmits mechanical forces in both directions.¹⁸

A striking demonstration comes from bone biology. When mesenchymal stem cells are grown on surfaces of different stiffness, the stiffer the surface, the more the cells upregulate α2-integrin and the more strongly they commit to becoming bone-forming cells. Knocking down α2-integrin blocks this stiffness-driven bone commitment, confirming that the integrin itself is the sensor in the chain, not a bystander.¹⁹ This finding has practical relevance for tissue engineering: designing scaffolds with the right mechanical properties can steer stem cells toward the desired tissue type, and integrins are the molecular link that makes that steering work.

Integrins and Cancer

Cancer’s relationship with integrins is a story of cooption. Normal cells depend on integrin-mediated attachment for survival: detach a healthy epithelial cell from the matrix and it undergoes a type of programmed death called anoikis. Cancer cells, by contrast, often rewire their integrin signaling to survive even when floating free, a prerequisite for spreading to distant organs. Highly metastatic colon cancer cells, for example, upregulate integrins α2 and β1 specifically in the detached state, and these integrins partner with growth factor receptors to activate pro-survival pathways that block the death signal.²⁰ Overexpression of the β4 integrin has been shown to constitutively activate a survival pathway, boosting resistance to anoikis and increasing the invasiveness of breast cancer cells.²¹

Tumors also rely on integrins to build their own blood supply. The integrin αvβ3 is upregulated on newly forming blood vessels in tumors but is largely absent from resting vessels in normal tissue.²² Early experiments showed that antibodies blocking αvβ3 could shut down new vessel growth stimulated by growth factors or tumor fragments without harming existing vessels.²³ This selectivity made αvβ3 look like an ideal drug target, since blocking it should starve the tumor without damaging normal blood supply.²⁴

Why Integrin-Targeted Drugs Have Struggled

Despite decades of excitement, turning integrin biology into successful drugs has been frustrating. Most integrin-targeting agents failed in late-stage clinical trials, and the few that reached the market were dogged by toxicity and limited effectiveness, often replaced by drugs aimed at other targets. The core problem was a combination of poor drug behavior in the body and the inherent complexity of integrin biology: blocking one integrin can shift signaling to another, and the same integrin can have opposite effects depending on context.²⁵

There have been bright spots. Natalizumab, the VLA-4 blocker for multiple sclerosis, is a genuine success, though it carries a rare but serious risk of a brain infection. Drugs targeting αIIbβ3 on platelets are used in acute settings like heart attacks. And research into fibrosis is generating renewed interest: several αv-containing integrins activate a growth factor called TGF-β that drives scarring in the lungs, liver, and kidneys, and preclinical models suggest that blocking integrin-mediated TGF-β activation can reduce fibrosis.²⁶ Among the candidates, integrins αvβ3, αvβ5, αvβ6, and αvβ8 have all been shown to modulate fibrosis through this TGF-β pathway in preclinical work.²⁷ The challenge, as always, is translating preclinical promise into drugs that work safely in people.

Viral Hijacking of Integrins

Because integrins sit on the cell surface and are designed to grab external partners, they are convenient entry points for viruses. A number of viruses carry short sequences on their outer proteins that mimic the natural ligands integrins evolved to recognize. By displaying an RGD-like motif, a virus can trick an integrin into binding it, then ride the integrin’s normal internalization machinery into the cell.²⁸ This strategy has been documented across a wide range of viruses, from adenoviruses to hantaviruses to foot-and-mouth disease virus.²⁹ Understanding which integrins a virus uses to enter cells can inform antiviral strategies, though blocking a host integrin comes with the same complexity problems that plague integrin-targeted cancer drugs.

Integrins in the Brain

Integrins are not confined to structural tissues and blood. In the brain, they sit at synapses, the junctions where neurons communicate, and play a role in synaptic plasticity, the ability of connections to strengthen or weaken over time. This makes them relevant to learning and memory. Research indicates that integrins are involved in the transmission of signals at synapses and contribute to the molecular machinery underlying memory formation; disruption of integrin signaling has been linked to various forms of cognitive impairment.³⁰ The picture is still emerging, but it underscores just how broadly integrins operate: even the brain’s most abstract functions appear to depend on the same adhesion receptors that hold skin together and seal wounds.

Stem Cells and Their Niches

Stem cells do not exist in isolation. They reside in specialized microenvironments called niches, where signals from surrounding cells and the matrix regulate whether they stay dormant, divide, or differentiate. Integrins are among the most important molecules shaping these niches. They help stem cells home to the correct location, stay anchored once they arrive, and receive the signals that control self-renewal versus differentiation. They even influence the orientation of cell division, which can determine whether a daughter cell remains a stem cell or commits to becoming a specialized tissue cell.³¹ In hematopoietic (blood-forming) stem cells, integrin-mediated adhesion to the bone marrow niche is essential for maintaining the reservoir of stem cells that replenishes your blood throughout your life.

An Ancient Protein Family

Given how central integrins are to animal biology, you might assume they evolved alongside multicellular animals. The real timeline is older than that. Core components of the integrin adhesion complex have been found in the genomes of single-celled organisms that diverged from the animal lineage long before multicellularity arose. One study identified integrin-related sequences in an apusozoan protist, placing the origin of the machinery before the split between the group containing animals and fungi.³² More recent genomic analyses suggest that the integrin-mediated adhesion complex was already present in the last common ancestor of a large supergroup of eukaryotes, meaning the protein family is hundreds of millions of years older than the animals that depend on it today.³³

Interestingly, fungi and choanoflagellates, the single-celled organisms most closely related to animals, appear to have independently lost key integrin components rather than never having them.³² Some integrin-related domains and other extracellular-matrix-associated proteins have also been identified in choanoflagellate genomes, though their functional roles remain unclear.³⁴ The prevailing view is that animals did not invent integrins from scratch but rather co-opted an existing toolkit, expanding and diversifying it to support the complex cell-cell and cell-matrix interactions that multicellular life demands. It is a reminder that some of the most fundamental molecular hardware in your body was already being assembled in organisms that had no tissues, no organs, and no need to close a wound.